Empowered Patient Podcast

Kathy Lee-Sepsick is the President, CEO, and Founder of Femasys, and not looking at minor levels of improvement in women's healthcare, but products and technologies that change the standard of care. With a focus on reproductive health, they are looking at infertility as well as a permanent birth control option for women.

Kathy explains, "So one of our major products is called FemVue. And what we did here is another example of what we're trying to do in these other product categories. We have developed a way to move an essential test for infertility diagnosis from radiology back to her GYN, utilizing ultrasound. So FemVue offers a saline and air contrast, or we call it bubbles, where those bubbles enable the evaluation and viewing of her fallopian tubes, which is suspect when a physician is evaluating all potential infertility factors."

"And at the same time, we are also advancing through clinical trial work, our FemBloc solution, which is our permanent birth control option for women. And both of those are delivered in an office environment. OBGYNs are performing the FemBloc procedure, and that's performed domestically as well in an active clinical trial."

@FemasysInc #ReproductiveHealth #WomensHealth #BirthControl #Infertility #FemBloc #FemVue

Femasys.com

Listen to the podcast here

Kathy Lee-Sepsick is the President, CEO, and Founder of Femasys, and not looking at minor levels of improvement in women's healthcare, but products and technologies that change the standard of care. With a focus on reproductive health, they are looking at infertility as well as a permanent birth control option for women.

Kathy explains, "So one of our major products is called FemVue. And what we did here is another example of what we're trying to do in these other product categories. We have developed a way to move an essential test for infertility diagnosis from radiology back to her GYN, utilizing ultrasound. So FemVue offers a saline and air contrast, or we call it bubbles, where those bubbles enable the evaluation and viewing of her fallopian tubes, which is suspect when a physician is evaluating all potential infertility factors."

"And at the same time, we are also advancing through clinical trial work, our FemBloc solution, which is our permanent birth control option for women. And both of those are delivered in an office environment. OBGYNs are performing the FemBloc procedure, and that's performed domestically as well in an active clinical trial."

@FemasysInc #ReproductiveHealth #WomensHealth #BirthControl #Infertility #FemBloc #FemVue

Femasys.com

Download the transcript here

Dr. Aharona Shuali is the Vice President of Medical Affairs at Nucleix developing a liquid biopsy to detect cancer. It can be a blood test or a urine test that looks at DNA, but it doesn't look at DNA as mutations. Rather, it's looking to detect changes in methylation which are small molecules that are sitting on the DNA and have shown to be much more important than mutations in the early detection of cancer.

Aharona explains, "What we do is a unique approach that is actually using enzymes. We have a very good signal-to-noise ratio. So I'll just talk a little bit about the standard. It is usually bisulfite, and bisulfite is a chemical that is very harsh. So it usually degrades, it ruins up to 90% of the DNA, and then it also introduces a lot of noise. So when you find the low amount of DNA in the blood that is coming from the tumor, if you treat it with bisulfite, you actually are going to destroy most of it. Then what is remaining is going to be very hard to tell if this is a real signal or it's actually noise."

"However, our platform is using a proprietary enzymatic-based approach, which actually does not destroy the DNA at all and has very low noise. So we believe that this approach can tell you, even with very minute amounts of DNA floating in the blood coming from the tumor, we'll be able to detect the signal from the tumor itself."

@nucleix2 #LungCancer #BladderCancer #LungEpiCheck #SanDiego

Nucleix.com

Listen to the podcast here

Dr. Aharona Shuali is the Vice President of Medical Affairs at Nucleix developing a liquid biopsy to detect cancer. It can be a blood test or a urine test that looks at DNA, but it doesn't look at DNA as mutations. Rather, it's looking to detect changes in methylation which are small molecules that are sitting on the DNA and have shown to be much more important than mutations in the early detection of cancer.

Aharona explains, "What we do is a unique approach that is actually using enzymes. We have a very good signal-to-noise ratio. So I'll just talk a little bit about the standard. It is usually bisulfite, and bisulfite is a chemical that is very harsh. So it usually degrades, it ruins up to 90% of the DNA, and then it also introduces a lot of noise. So when you find the low amount of DNA in the blood that is coming from the tumor, if you treat it with bisulfite, you actually are going to destroy most of it. Then what is remaining is going to be very hard to tell if this is a real signal or it's actually noise."

"However, our platform is using a proprietary enzymatic-based approach, which actually does not destroy the DNA at all and has very low noise. So we believe that this approach can tell you, even with very minute amounts of DNA floating in the blood coming from the tumor, we'll be able to detect the signal from the tumor itself."

@nucleix2 #LungCancer #BladderCancer #LungEpiCheck #SanDiego

Nucleix.com

Download the transcript here

Nataly Youssef Ph.D. is the Co-Founder of Reclaim Health trained as an industrial engineer, with expertise in operations research, AI, and big data.

Nataly explains, "So this is the genesis of Reclaim. Really being able to provide that tool for patients, to be able to be well informed about both their health insurance and then to be able to manage their healthcare bills in the very context of that health insurance, all data-driven basically. This is all personalized to their own claims data, to their own information, and to provide them with these actionable items, actionable recommendations, in the context of their own journey."

"We sort of say, most of the people that I ask recommended X, Y, and Z, and that's why I'm going with X, Y, and Z. But imagine AI doing exactly the same, but at a scale of asking millions of people that could look like you. And, as a result, be able to really democratize these insights of all of our experiences and being able to make it available to each one of us. But the importance not only is in the AI, but it's how you actually represent the insights from AI so that they are actionable for someone."

@reclaimapp #HealthInsurance #DigitalHealth #HealthSavings #AIinHealth #AI

ReclaimHealth.com

Listen to the podcast here

Nataly Youssef Ph.D. is the Co-Founder of Reclaim Health trained as an industrial engineer, with expertise in operations research, AI, and big data.

Nataly explains, "So this is the genesis of Reclaim. Really being able to provide that tool for patients, to be able to be well informed about both their health insurance and then to be able to manage their healthcare bills in the very context of that health insurance, all data-driven basically. This is all personalized to their own claims data, to their own information, and to provide them with these actionable items, actionable recommendations, in the context of their own journey."

"We sort of say, most of the people that I ask recommended X, Y, and Z, and that's why I'm going with X, Y, and Z. But imagine AI doing exactly the same, but at a scale of asking millions of people that could look like you. And, as a result, be able to really democratize these insights of all of our experiences and being able to make it available to each one of us. But the importance not only is in the AI, but it's how you actually represent the insights from AI so that they are actionable for someone."

@reclaimapp #HealthInsurance #DigitalHealth #HealthSavings #AIinHealth #AI

ReclaimHealth.com

Download the transcript here

Dr. Waqaas Al-Siddiq is the Founder and CEO of Biotricity and a leader in the development of mobile cardiac telemetry, MCT, devices to provide real-time, continuous monitoring of at-risk patients.

Waqaas explains, "One of the core areas that we strongly focus on is long-term data collection in this real-time intelligent monitoring. When you talk about our core product, which is Bioflux, which is used for diagnostics, we are talking about a device that has built-in algorithms, that's FDA cleared, as well as the algorithms to collect data from a patient, determine if there is an emergency or an anomaly, and then alert somebody for emergency response.

"Most importantly, we have three channels of data. Three channels of data means that we have three different views of the heart. What that does is that it creates more data. More data means better accuracy and a better diagnosis. The standard in the MCT space is actually two channels. With three contact points, two channels. To get three contact points, you need five access points. That's what everybody else is doing in the industry. But then patients don't like five connectivity points. These devices are just more cumbersome to wear. What we did at Biotricity, which is incredibly unique, is to create a three channel, three contact point system, which is proprietary to us. This leads to better algorithms and better analytics."

@Biotricity_Inc $BTCY #MedTech #MedicalDevice #Healthcare #ChronicDisease #Cardiology #CardiacCare #Diagnostics #Prevention #Patient

Biotricity.com

Download the transcript here

Dr. Waqaas Al-Siddiq is the Founder and CEO of Biotricity and a leader in the development of mobile cardiac telemetry, MCT, devices to provide real-time, continuous monitoring of at-risk patients.

Waqaas explains, "One of the core areas that we strongly focus on is long-term data collection in this real-time intelligent monitoring. When you talk about our core product, which is Bioflux, which is used for diagnostics, we are talking about a device that has built-in algorithms, that's FDA cleared, as well as the algorithms to collect data from a patient, determine if there is an emergency or an anomaly, and then alert somebody for emergency response.

"Most importantly, we have three channels of data. Three channels of data means that we have three different views of the heart. What that does is that it creates more data. More data means better accuracy and a better diagnosis. The standard in the MCT space is actually two channels. With three contact points, two channels. To get three contact points, you need five access points. That's what everybody else is doing in the industry. But then patients don't like five connectivity points. These devices are just more cumbersome to wear. What we did at Biotricity, which is incredibly unique, is to create a three channel, three contact point system, which is proprietary to us. This leads to better algorithms and better analytics."

@Biotricity_Inc $BTCY #MedTech #MedicalDevice #Healthcare #ChronicDisease #Cardiology #CardiacCare #Diagnostics #Prevention #Patient

Biotricity.com

Download the transcript here

Dr. Jennifer Jones-McMeans is the Divisional Vice President of Global Clinical Affairs at Abbott's Vascular Business. She talks about recently released data from their Beyond Intervention Survey of 1800 stakeholders including 1289 vascular disease patients, 408 healthcare physicians, and 173 healthcare leaders from across 13 countries. The study looked particularly at Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD) which revealed these diseases disproportionately affect Black, Latino, and Native Americans.

Jennifer reports, "I think what Beyond Intervention allowed us to do is to see what the patient is feeling, experiencing, and how does that differ from what your healthcare provider or your healthcare leader is saying? Because one of the key findings that we found was that patient experience is maybe not as good as the healthcare provider may be thinking it is."

"And we know that when you look at these social determinants, and they can be anything from socioeconomic status, availability to care, education, impact of income, they all collide. And many times in certain areas, they can collide with race and ethnicity. So when you put people in an environment that is not supportive of health and that you're just reaching so many of the things that I spoke of before, you put them at risk for development of diseases, such as PAD and CAD."

@AbbottCardio #ClinicalTrials #VascularDisease #PAD #PeripheralArteryDisease #CAD #CoronaryArteryDisease #SDOH #SocialDeterminantsofHealth

Abbott.com

Listen to the podcast here

Dr. Jennifer Jones-McMeans is the Divisional Vice President of Global Clinical Affairs at Abbott's Vascular Business. She talks about recently released data from their Beyond Intervention Survey of 1800 stakeholders including 1289 vascular disease patients, 408 healthcare physicians, and 173 healthcare leaders from across 13 countries. The study looked particularly at Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD) which revealed these diseases disproportionately affect Black, Latino, and Native Americans.

Jennifer reports, "I think what Beyond Intervention allowed us to do is to see what the patient is feeling, experiencing, and how does that differ from what your healthcare provider or your healthcare leader is saying? Because one of the key findings that we found was that patient experience is maybe not as good as the healthcare provider may be thinking it is."

"And we know that when you look at these social determinants, and they can be anything from socioeconomic status, availability to care, education, impact of income, they all collide. And many times in certain areas, they can collide with race and ethnicity. So when you put people in an environment that is not supportive of health and that you're just reaching so many of the things that I spoke of before, you put them at risk for development of diseases, such as PAD and CAD."

@AbbottCardio #ClinicalTrials #VascularDisease #PAD #PeripheralArteryDisease #CAD #CoronaryArteryDisease #SDOH #SocialDeterminantsofHealth

Abbott.com

Download the transcript here